Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

Diabetic nephropathy (DN) is the leading cause of end‐stage renal disease worldwide.
Chronic hyperglycemia and high blood pressure are the main risk factors for the …

血管内皮细胞和内皮细胞释放的活性因子是调控血管舒张功能的重要因素. 糖尿病是慢性心血管
疾病的高危因素之一. 目前认为高糖和糖尿病引起的内皮细胞功能障碍是造成血管功能改变 …

随着经济高速发展和工业化进程的加速, 生活方式的改变和老龄化进程的加速,
使我国糖尿病的患病率正呈快速上升的趋势, 成为继心脑血管疾病, 肿瘤之后另一个严重危害 …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

Since the introduction of insulin almost a century ago, more than 80 peptide drugs have
reached the market for a wide range of diseases, including diabetes, cancer, osteoporosis …

Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Stroke is the leading cause of disability and thesecond leading cause of death worldwide.
With the global population aged 65 and over growing faster than all other age groups, the …

Dynamic interactions between gut microbiota and a host's innate and adaptive immune
systems are essential in maintaining intestinal homeostasis and inhibiting inflammation. Gut …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …